No Detail Found!

Impact of Different Treatment Modalities on the Outcome of Pancreatic Cancer.

Author(s)
Misbah Khan Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan
Muhammad Ijaz Ashraf Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan
Aamir Ali Syed Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan
Faisal Hanif Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan
Abstract
Objective: To analyze overall survival patterns of our pancreatic cancer patient population managed with a curative or palliative intent. Study Design: Analytical study. Place and Duration of Study: Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, from January 2000 till February 2015. Methodology: A retrospective review of the data of all of our pancreatic cancer patients was performed, using the hospital information system. Patients with tumor other than adenocarcinoma or a histopathologic diagnosis not made at our hospital are excluded from the study, along with patients having an incomplete medical record for all included variables. The main outcome measure was overall survival in months from the date of diagnosis. All results were segregated and analyzed according to the intervention modality used, i.e. group A: surgery with curative intent, group B: Palliative chemotherapy, and group C: Supportive care. Results were controlled for the confounding variables including age, gender, significant comorbid conditions, stage of disease at initial presentation, tumor location, and histological grade. Results: Among the 197 patients fulfilling the inclusion criteria, 21 (10.7%) were excluded as they were lost to follow-up. Overall Kaplan-Meier survival analysis gave a 56% one-year survival, 22% at 3- and 16% at 5-year. The subset analysis on Cox-regression survival plot showed inferior survival with advancing stage of the disease and a treatment less than definitive surgical resection and adjuvant chemotherapy. On Cox-proportional regression analysis, stage of the disease and treatment modality were only independent predictive factors for overall survival (p < 0.01). Conclusion: Stage for stage, surgery with curative intent (group A) or palliative chemotherapy (group B) showed a trend towards improved survival as compared to supportive management (group C) alone. The results were more significant for surgical resection arm.
Publication Details
Page(s) 470-474
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 27, Issue: 8, Year: 2017

Request the full text from PASTIC

References
O'Neill,CB , Atoria,CL , O'Reilly,EM , La Femina,J , Henman,MC , Elkin,EB, 2012.Costs and trends in pancreatic cancer treatment,Cancer 118 5132 -9
KhoranaAA,ManguPB,BerlinJ,EngebretsonA,HongTS,MaitraA, 2016.Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline,J Clin Oncol 31 -
FeigBW,ChingCD, 2012.The MD Anderson surgical oncology handbook, 472 -90
MartinLK,LuuDC,LiX,MuscarellaP,EllisonEC,BloomstonM, 2014.The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a singleinstitution experience,Ann Surg Oncol 21 862 -7
2016.National comprehensive cancer network. NCCN clinical practice guidelines in oncology,Pancreatic adenocarcinoma, v.2 -
NeoptolemosJ,PalmerD,GhanehP,ValleJW,CunninghamD,WadsleyJ, 2016.ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma,Pancreatology 16 S63 -
NeoptolemosJ,BüchlerM,StockenDD,GhanehP,SmithD, 2009.: A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/ folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma,J Clinical Oncol 27 LBA4505 -
ZahirMN,JabbarAA, 2015.Metastatic pancreatic carcinoma and experience with FOLFIRINOX - a cross-sectional analysis from a developing country,Asian Pac J Cancer Prev 16 6001 -6
SiegelR,NaishadhamD,JemalA, 2013.,CA Cancer J Clin 63 11 -30
EdgesSB,ComptonCC, 2010.The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM,Ann Surg Oncol 17 1471 -4
GongJ,TuliR,ShindeA,HendifarAE, 2016.Meta-analyses of treatment standards for pancreatic cancer,Mol Clin Oncol 4 315 -25
RaiganiS,AmmoriJ,KimJ,HardacreJM, 2014.Trends in the treatment of resectable pancreatic adenocarcinoma,J Gastrointest Surg 18 113 -23
MillerRC,LottMJ,CorsiniMM, 2009.Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from mayo clinic for the 5th JUCTS symposium,Int J Radiat Oncol Biol Phys 75 364 -8
StathisA,Moore MJ, 2010.Advanced pancreatic carcinoma: current treatment and future challenges,Nat Rev Clin Oncol 7 163 -72
AhmadZ,MinhasK,MoeenS,AhmedA, 2015.Epidemiologic data, tumor size, histologic tumor type and grade, pathologic staging and follow-up in cancers of the ampullary region and head of pancreas in 311 Whipple resection specimens of Pakistani patients,Asian Pac J Cancer Prev 16 7541 -6
YuZ,ZhongW,TanZM,WangLY,YuanYH, 2015.Gemcitabine adjuvant therapy for resected pancreatic cancer, A meta-analysis,Am J Clin Oncol 38 322 -5
WolfgangCL,HermanJM,LaheruDA,KleinAP,ErdekMA,FishmanEK, 2013.Recent progress in pancreatic cancer,CA Cancer J Clin 63 318 -48
BayraktarS,BayraktarUD,Rocha-LimaCM, 2010.Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer,World J Gastroenterol 16 673 -82
LiaoWC,ChienKL,LinYL,WuMS,LinJT,WangHP, 2013.Adjuvant treatments for resected pancreatic adenocarcinoma, A systematic review and network meta-analysis,Lancet Oncol 14 1095 -103
0

Citations

0

Downloads

79

Views